Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontunisertib versus placebo in fibrostenosing Crohn’s disease
NL-OMON61635Phase 2Not yet recruiting
- Sponsor
- Agomab Therapeutics
- Start
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in fibrostenotic Crohn's disease comparing Ontunisertib with Placebo (2 arms). Primary endpoint: Endoscopic passability of the ileal index stricture at Week 24. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
ontunisertib
03
Conditions
fibrostenotic Crohn's disease
Beyond the preview
Go deeper on NL-OMON61635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61635.